DNA Microarray Market Size and Share Analysis by Type (Complementary, Oligonucleotide), Application (Gene Expression Analysis, Genotyping), End User (Pharmaceutical and Biotechnology Companies, Diagnostic Centers, Hospitals and Clinics, Academic and Research Institutes) - Global Industry Demand Forecast to 2030

DNA Microarray Market Size & Share

The global DNA microarray market generated revenue of USD 1,982.1 million in 2023, which will reach USD 3,930.8 million by 2030, advancing at 10.5% CAGR between 2024 and 2030. The growth of this market is attributed to the rising incidence of cancer globally, increasing utilization of this technology in its detection, and revolution in information technology, including software.

• DNA microarray has number of applications, such as agricultural biotechnology, disease diagnosis & monitoring, protein expression & proteomics, cancer diagnosis, and the discovery of new drug molecules.
• The rising investment in research activities and the increasing usage of the technology in gene expression drive the market growth.
• Other factors driving the growth of the market are the increasing demand for personalized medicine and improving disease diagnosis technology.

The rising global burden of cancer is one of the most-significant growth factors for this market. Many recent studies have demonstrated the efficacy of DNA microarrays for the classification of soft-tissue malignancies and determining the primary sites of metastatic tumors. According to the World Health Organization, cancer is one of the leading causes of death globally, accounting for nearly 10 million deaths every year. The leading cancers in terms of deaths are lung,   liver, stomach, breast, colon, and rectum.

Furthermore, the growing utilization of this technology for discovering biomarkers, for the discovery of disease-related genes and diagnosis of diseases, is expected to create a new opportunity for the DNA microarray market in the forthcoming period.

• Biopharmaceutical companies are increasingly focusing on the discovery and development of new drugs due to the rising prevalence of diseases such as tuberculosis, cancer, genetic disorders, and, recently, the SARS-CoV-2 virus.
• In April 2021, the National Center of Biotechnology Information (NCBI) published a study demonstrating the efficacy of the CovidArray to detect the N1 and N2 markers of SARS-CoV-2 in nasopharyngeal swabs.
• The microarray-based assay is built on the phenomenon of solid-phase fluorescently labeled amplicon hybridization following reverse transcription and the extraction of the RNA.

Governments are also supporting the players in setting up research facilities for vaccines and therapeutics for such diseases. Additionally, this technology is being widely utilized in herbal drug research & development.

In addition, various strategic initiatives are taken by the key players, such as partnerships a collaborations, to strengthen their personalized therapeutics and genotype capabilities.

• In May 2022, the Qatar Genome Program announced a collaborative partnership with Thermo Fisher Scientific Inc. to give a boost to the genomic study and clinical applications of prognostic genomics in Qatar.
• This collaboration expanded the advantages of personalized medicine across the Middle East.
• Furthermore, the agreement covers custom genotyping arrays designed to boost the scientific application of prognostic genomics.

Growing Use of Personalized Medicine

DNA microarrays are important in personalized medicine because they can be used for a wide range of purposes, including diagnosis, prognosis, and targeted therapies for many conditions. Primarily, due to some restrictions in the diagnosis and treatment of diseases via traditional methods, personalized medicine has gained recognition. Among these, the most significant of these are cancer and immunologic disorders, the prognosis and treatment of which depend on the understanding of every individual patient’s genome. Hence, the rising demand for personalized medicine is one the main factors driving the growth of the market.

Explore more about this report - Request free sample

Increasing Application Areas of DNA Microarrays

• The DNA microarray technology is mainly used in genome mapping and sequencing applications.
• But, over the last few years, its utilization has been gradually rising in the diagnosis & detection of infectious and genetic diseases, cancer diagnostics, drug discovery, pharmacogenomic research, and forensic applications.
• Moreover, it is used during research in immunology, such as the study of the relation between the phenotype and gene expression, analysis of the molecular mechanisms of allergy, activation & differentiation of immune cells, regulation of immune responses, and immunological pharmacology.
• In addition to this, the advanced applications of such microarrays in genetic factor expression would offer players a new customer base and field of medicine to tap.

Oligonucleotide DNA Microarray Held Largest Revenue Share

Based on type, the oligonucleotide DNA microarray category accounts for the largest share, of 70%, and it is further expected to maintain its dominance in the future. The growth of this category is attributed to the advantages of these products, such as cost-effectiveness and an exceptional capability to monitor the expression of every gene in the genome.

Additionally, the control it offers over hybridization specificity makes it the most-prominent method for the analysis of single nucleotide polymorphisms.

The cDNA microarray category is expected to register the highest growth rate over the forecast period.

• This is because it is useful in studying the expression of genes in various species.
• Moreover, the increasing use of cDNA microarrays in the screening of polymorphisms, discovering of genes, and mapping of genomic DNA clones helps in the growth of this category.

Pharmaceutical & Biotechnology Companies Dominate Market

Based on end user, the pharmaceutical & biotechnology category accounted for the largest share, of 40%, in 2023, and it is set to maintain its dominance in the future. This is owing to the growing adoption of DNA microarrays in drug discovery and research applications. In this regard, the growth in the research activity for finding new drug molecules supports the market advance in this category. The understanding of the importance of the Human Genome Project has opened new opportunities for the usage of this technology in cancer research. A growing number of molecular markers with a prognostic and diagnosis potential are being identified For a broad range of human cancer with cDNA microarray analysis.

Hospitals & diagnostic centers will showcase the fastest growth over the forecast period.

• In today’s highly advanced laboratories in hospitals and diagnostic centers, the DNA microarray technology is emerging as an advanced and powerful tool for the transformation of clinical diagnostics.
• This technique makes it possible to detect a great number of polymorphisms in a single assay by using a DNA chip or biochip.
• Furthermore, DNA microarray assays can be performed in fully automated, molecular diagnostic platforms, and multiplexing.

Therefore, companies in the market are expanding their portfolio of products for hospitals and diagnostic centers that help in the detection of autoimmune diseases, cancers, communicable diseases, and other inherited-mutation-related diseases. For instance, Applied Microarrays LLC offers custom arrays to diagnose various communicable diseases and cancers. In addition to this, some other diseases detectable by these products include diet-related diseases, such as dysbiosis, celiac, and general food intolerance.

North America Dominates Market

Geographically, North America held the largest share, of around 40%, in 2023, and it is expected to grow at a robust CAGR during the review period.

• This is due to the presence of key market players in the region and the growing investment by them for developing technologically advanced DNA microarray products.
• Furthermore, the rising prevalence of difficult-to-diagnose and treat diseases in the region and the development of innovative experimental replicas for research purposes as well as the discovery of therapeutics raise the demand for microarrays to a significant extent.

Furthermore, the market in Canada is growing rapidly on account of its advanced healthcare infrastructure, government initiatives for enhancing access to effective diagnosis services, surge in the incidence of chronic diseases, and presence of key players.

In the same way, the growth of the market in Europe is due to the advancement of the health infrastructure and rise in the incidence of infectious diseases and cancer.

• The increasing investments in the field of biotechnology industry is another major factor driving the market revenue growth in this region.
• Essentially, the high adoption of the DNA microarray technology in research related to drug discovery and disease diagnosis is accelerating the regional industry’s growth.

Furthermore, the adoption of this technology is quickly rising in Germany due to an increase in the prevalence of cancer, expansion of screening practices, and technological advancements in specialized testing. Moreover, The Government of Germany is taking initiatives to make people aware of early and effective disease diagnosis and improve the access to the associated services.

Top DNA Microarray Solution Providers Are:

• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Merck KGaA
• PerkinElmer Inc.
• Applied Microarrays LLC
• Savyon Diagnostics

Market Breakdown

This report offers deep insights into the DNA microarray market, with size estimation for 2017 to 2030, the major drivers, restraints, trends and opportunities, and competitor analysis.

Segment Analysis, By Type

• Complementary
• Oligonucleotide

Segment Analysis, By Application

• Gene Expression Analysis
• Genotyping

Segment Analysis, By End User

• Pharmaceutical and Biotechnology Companies
• Diagnostic Centers
• Hospitals and Clinics
• Academic and Research Institutes

Region/Countries Reviewed for this Report

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.